Drug Trial Radar · NCT01366209
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 20, 2026Latest source record: Apr 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
555
Actual
Start
Jun 2011
Primary completion
Feb 2014
Study completion Feb 2014
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 3, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study objectives are to confirm the treatment effect of pirfenidone compared with placebo on change in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo in patients with IPF.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
PirfenidoneDrug
Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
PlaceboDrug
Placebo equivalent given as 3 divided doses 3 times per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52Time frame: 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
InterMune Inc.
Brisbane, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.